These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 3425599)

  • 41. Identification and characterization of a novel mutation c.1090G>T (G325W) and nine common mutant alleles leading to Gaucher disease in Spanish patients.
    Torralba MA; Pérez-Calvo JI; Pastores GM; Cenarro A; Giraldo P; Pocoví M
    Blood Cells Mol Dis; 2001; 27(2):489-95. PubMed ID: 11259172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical variation in 2 related children with neuronopathic Gaucher disease.
    Grover WD; Tucker SH; Wenger DA
    Ann Neurol; 1978 Mar; 3(3):281-3. PubMed ID: 96723
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heterozygote detection of type I Gaucher disease using blood platelets.
    Nakagawa S; Kumin S; Sachs G; Nitowsky HM
    Prog Clin Biol Res; 1982; 95():597-602. PubMed ID: 6812088
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical and enzyme studies in Gaucher disease.
    Kaur M; Kabra M; Kher A; Naik G; Bharucha BA; Verma IC
    Indian Pediatr; 1996 Sep; 33(9):735-8. PubMed ID: 9057400
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-neuronopathic Gaucher disease due to saposin C deficiency.
    Tylki-Szymańska A; Czartoryska B; Vanier MT; Poorthuis BJ; Groener JA; Ługowska A; Millat G; Vaccaro AM; Jurkiewicz E
    Clin Genet; 2007 Dec; 72(6):538-42. PubMed ID: 17919309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhanced enzyme activity after incubation with zinc can be used to distinguish heterozygotes of Pompe's disease.
    Lin CY
    Pediatr Res; 1988 Mar; 23(3):283-7. PubMed ID: 3281122
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gaucher disease of the Norrbottnian type (type III). Phenotypic manifestations.
    Svennerholm L; Dreborg S; Erikson A; Groth CG; Hillborg PO; Håkansson G; Nilsson O; Tibblin E
    Prog Clin Biol Res; 1982; 95():67-94. PubMed ID: 6812091
    [No Abstract]   [Full Text] [Related]  

  • 48. Biochemical and molecular characterization of adult patients with type I Gaucher disease and carrier frequency analysis of Leu444Pro - a common Gaucher disease mutation in India.
    Sheth J; Pancholi D; Mistri M; Nath P; Ankleshwaria C; Bhavsar R; Puri R; Phadke S; Sheth F
    BMC Med Genet; 2018 Oct; 19(1):178. PubMed ID: 30285649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectors of three beta-glucosidases from human liver.
    Daniels LB; Gnarra JR; Glew RH
    Prog Clin Biol Res; 1982; 95():333-55. PubMed ID: 6812077
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease.
    Halperin A; Elstein D; Zimran A
    Blood Cells Mol Dis; 2006; 36(3):426-8. PubMed ID: 16651014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A flow cytometric assay for lysosomal glucocerebrosidase.
    van Es HH; Veldwijk M; Havenga M; Valerio D
    Anal Biochem; 1997 May; 247(2):268-71. PubMed ID: 9177687
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sodium taurocholate effect on beta-glucosidase activity: a new approach for identification of Gaucher disease using the synthetic substrate and leucocytes.
    Magalhães J; Sá Miranda MC; Pinto R; Lemos M; Poenaru L
    Clin Chim Acta; 1984 Aug; 141(2-3):111-8. PubMed ID: 6435915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prenatal diagnosis of Gaucher's disease (author's transl)].
    Heilbronner H; Wurster KG; Harzer K
    Dtsch Med Wochenschr; 1981 May; 106(20):652-4. PubMed ID: 7227212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthetic substrate beta-glucosidase activity in leukocytes: a reproducible method for the identification of patients and carriers of Gaucher's disease.
    Wenger DA; Clark C; Sattler M; Wharton C
    Clin Genet; 1978 Feb; 13(2):145-53. PubMed ID: 23912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of chronic gamma radiosensitivity as an in vitro assay for heterozygote identification of ataxia-telangiectasia.
    Weeks DE; Paterson MC; Lange K; Andrais B; Davis RC; Yoder F; Gatti RA
    Radiat Res; 1991 Oct; 128(1):90-9. PubMed ID: 1924732
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In situ radiation-inactivation size of fibroblast membrane-bound acid beta-glucosidase in Gaucher type 1, type 2 and type 3 disease.
    Choy FY; Woo M; Potier M
    Biochim Biophys Acta; 1986 Mar; 870(1):76-81. PubMed ID: 3947649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Carrier detection of pyruvate carboxylase deficiency in fibroblasts and lymphocytes.
    Atkin BM
    Pediatr Res; 1979 Oct; 13(10):1101-4. PubMed ID: 116187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gaucher-like changes in human blood-derived macrophages induced by beta-glucocerebrosidase inhibition.
    Yatziv S; Newburg DS; Livni N; Barfi G; Kolodny EH
    J Lab Clin Med; 1988 Apr; 111(4):416-20. PubMed ID: 3351378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The cytosolic β-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation.
    Dekker N; Voorn-Brouwer T; Verhoek M; Wennekes T; Narayan RS; Speijer D; Hollak CE; Overkleeft HS; Boot RG; Aerts JM
    Blood Cells Mol Dis; 2011 Jan; 46(1):19-26. PubMed ID: 20728381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.